Insights Into Metastatic Colorectal Cancer (mCRC)
Perspectives on treatment practices in mCRC, including the frontline treatment landscape, third-line-and-later treatment options, and management of refractory mCRC by community oncologists.
Central – March 28, 2026
Faculty Chair
Michael Morse, MD, FACP
Duke Cancer Center, Durham, NC, USA
West – May 16, 2026
Faculty Chair
Tanios Bekaii-Saab, MD, FACP, FASCO
Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ, USA
Insights Obtained From
- Texas
Insights Obtained From
- California, Nevada
REPORT SNAPSHOT
- Frontline treatment landscape in mCRC
- Management of refractory mCRC
- Third-line-and-later treatment decisions for microsatellite-stable mCRC
- Detailed insights and attendee takeaways
- ARS data
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through the use of audience response system questioning and moderated discussion
- The group of experts comprised 10–15 community oncologists representative of each region
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.